

FAX

GlaxoSmithKline

To Art Unit 1617, Examiner M. Bahar
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Valerie L. Phillips
.....
Tel 919-483-8223 Fax 919-483-5730
.....
E-mail Vlp47157@gsk.com
.....
Date June 17, 2004 Pages including cover 31
.....
Subject Amendment, Petition and Fee Adding Inventors
.....
For Claims To Previously Unclaimed Subject
.....
Matter
.....

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com


Serial No.: 10/049,142
Date: February 5, 2002
Applicant: Clayton et al.
Title: Use of EP4 Receptor Ligands in the Treatment of Neuropathic Pain and Colon Cancer

Attached:
Transmittal Form w/Certificate of transmission via facsimile
Amendment, Petition and Fee Adding Inventors For Claims To Previously Unclaimed Subject Matter
(duplicate)
Statement Under 37 CFR 1.48c of Reasons for Adding Inventors and Of No Deceptive Intent (4 statements)
Declarations (6)
Consent of Assignee To Add Names Of Inventors Of an Invention Originally Disclosed And Now Being
Claimed In An Application Pursuant To 37 CFR 1.48c(5)
Certificate Under 37 CFR 3.73(b)

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this transmittal is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306) on June 17, 2004.


Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PG3749USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: N. Clayton, et al.

Serial No. 10/049,142

Examiner: M. Bahar

Filing Date: 5 Feb 2002

Art Unit: 1617

For: USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT
OF NEUROPATHIC PAIN AND COLON CANCER

OFFICIAL

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450AMENDMENT, PETITION AND FEE ADDING INVENTORS FOR CLAIMS TO
PREVIOUSLY UNCLAIMED SUBJECT MATTER (37 C.F.R. § 1.48(c))

1. Applicants hereby petition to amend inventorship of the instant application
to add the following named inventors.

MARK BAMFORD

RICHARD GREEN (DECEASED)

RICHARD COLES

2. Claims now on file

The claims in this application are as follows:

- ☐ originally filed claim(s) _____
- ☐ originally filed claims (s) _____
- as amended on _____
- ☒ claim(s) 5-6, 14-15, 19-20, 22-29 and 30-37
- filed on 5 February 2002 and 13 February 2004
- ☒ claim(s) 21
- filed on 5 February 2002, as amended on 13 Feb 2004.

PG3749USw

3. Status of Inventorship After Amendment

☒ At the time of the invention now being claimed, all inventors were under an obligation to assign the inventions to a common assignee and thus all now claimed inventions are commonly owned.

4. Statement From Each Person Being Added As Inventor (37 C.F.R. § 1.48(c)(2)):

☒ Attached is a statement from each person being added as an inventor, or their representative, that the addition of the inventor is necessitated by amendment of the claims and that the inventorship error occurred without deceptive intent on his or her part.

5. Declaration (37 CFR 1.48(c)(3)):

☒ Attached is a declaration by the actual inventor or inventors as required by 37 CFR 1.63

6. Consent of the Assignee (37 CFR 1.48(c)(5)).

☒ Attached is the written consent of the assignee of the originally named inventor(s).

7. An Assignment from the originally named inventors to SmithKline Beecham Corp. was recorded on 16 October 2003 at reel 014048, frame 0581. An Assignment from Mark Bamford, Richard Green (deceased) and Richard Coles to SmithKline Beecham Corp., was recorded on 25 May 2004 at reel 014652, frame 0163.

8. Fee (37 CFR 1.17(i))

The fee required (37 C.F.R. § 1.20(b)) is paid as follows:


☒ Authorization is hereby made to charge the amount of the \$130.00 to Deposit Account No. 07-1392.

☒ Please charge any additional fees required in connection with this petition or credit any overpayment to Deposit Account No. 07-1392.

PG3749USw

☒ A duplicate of this paper is attached.

Respectfully Submitted



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Dated: 6/17/2004
GlaxoSmithKline Inc.
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
919 483-2723
fax: 919 483-7988
email: Lorie.A.Morgan@gsk.com